Intracavernous Self-Injection with Papaverine and Phentolamine for the Treatment of Erectile Dysfunction.
- Author:
Chung Hwan OH
1
;
Sae Chul KIM
Author Information
1. Chang-Ang University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
intracavernous injection;
papaverine;
phentolamine
- MeSH:
Erectile Dysfunction*;
Follow-Up Studies;
Hematoma;
Humans;
Male;
Papaverine*;
Penile Prosthesis;
Phentolamine*;
Priapism;
Treatment Refusal
- From:Korean Journal of Urology
1989;30(5):760-768
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A total or 76 patients of erectile dysfunction were treated with intracorporeal self-injection of Papaverine hydrochloride(30mg/ml) and Phentolamine mesylate(1mg/ml) from Feb. 1986 to Aug. 1988. The results were obtained as follows: 1. The average patient age was 48.1 years, with a range of 26 to 72 years. The etiology of impotence were psychogenic in dosages patients (47.4 %), vasculogenic in 32 (42.1 %) and neurogenic in 4 (5.3%). 2. The average effective dosages were 0.44ml in psychogenic impotence, 0.69ml in vasculogenic and 0.16ml in neurogenic. 3. The erection time was 60 minutes in 14 (70.0%) out of 20 psychogenic impotence, 30-60minutes in 8 (50.0% ) out of 16 vasculogenic and 90-120 minutes in all neurogenic. 4. The durations of treatment were 1-3months in 12 patients (33.3% ) and 12-24months in 7(19. 5%). The average duration of treatment was 6.9months. 5. Complications included priapism in 7 patients, subcutaneous hematoma in 2, induration of injection site in 1 and fibrous plaque on cavernosal body in 1. 6. Of the 76 patients, 40 patients discontinued injection due to improved potency in 14 patients, penile prosthesis in 4, refusal of treatment in 3 and failure to follow-up in 19. Therefore, intracorporeal self-injection of Papaverine hydrochloride and Phentolamine mesylate seems to be safe and effective primary choice of treatment for selective impotence.
